Summary Tumour growth depends on neovascularisation and tumour cell proliferation. Factor VIII-related antigen (F-VIII RA) localises to vascular endothelium. Expression of proliferating cell nuclear antigen (PCNA) is correlated with cell proliferation. We investigated the correlation between the expression of these antigens and prognosis in gastric carcinoma. A total of 108 specimens resected from patients with gastric carcinoma were investigated by staining with monoclonal antibodies against F-VIII RA and PCNA. Microvessel 
Recently, it has been suggested that the degree of tumour angiogenesis is related to malignant potential (Folkman, 1990; Bosari et al., 1992) . Cellular proliferative activity has also been suggested as a useful marker for the malignant potential of various carcinomas (Sowa et al., 1988; Van Dierendonck et al., 1989) . In recent years, many studies have reported on the relationship between tumour angiogenesis, tumour cell proliferation and clinical outcome (Bouzubar et al., 1989; Weidner et al., 1992; Gasparini et al., 1994) . Weidner et al. (1992) have shown that, in patients with breast cancer, both relapse-free and overall survival rates decrease with increasing microvessel count. In this study microvessels were highlighted by staining for factor VIII-related antigen (F-VIII RA) or von Willebrand factor, which can be localised to vascular endothelium in tissue sections by immunofluorescence and immunoperoxidase techniques. Proliferating cell nuclear antigen (PCNA), an auxiliary protein for DNA polymerase 6, plays an important role in DNA synthesis and is thought to be localised to nuclei, particularly during late GI and S-phases (Garcia et al., 1989; Landberg et al., 1990) . In this context, PCNA has drawn attention as a marker for cell proliferation.
In this study, we investigated the correlation between prognosis and angiogenesis and cell proliferation in gastric cancer as demonstrated by immunohistochemical staining of F-VIII RA and PCNA respectively. Materials (Figure 1 ). Branching structures were counted as a single vessel unless there was a break in the continuity of the structure. The stained sections were screened at 5 x magnification to identify the areas of highest vascular density within the tumour from all tissue blocks. These high-vascularity areas could occur anywhere within the tumour, but occurred most frequently at the margins of the carcinoma. Sclerotic areas, where microvessels were sparse, and areas immediately adjacent to benign tissue were not considered in vessel counts. Vessels were counted in the five areas of highest vascular density at 200 x magnification (x 20 objective and x 10 ocular, 0.785 mm2 per field). Microvessel count (MVC) was expressed as the mean number of vessels in these areas. The two investigators' counts were significantly correlated (by Spearman rank correlation test; r = 0.621, P<0.01), therefore the average of the two investigators' counts was taken for further analysis.
Scoring of PCNA Only nuclear staining was accepted as positive ( Figure 2 ). All labelled nuclei were regarded as positive. Nuclei from more than 500 tumour cells were counted microscopically among the five areas with the highest density of PCNA expression from all tissue blocks. The PCNA labelling index (PCNA LI) was calculated as the percentage of positive cell nuclei. Although the two investigators did not agree exactly regarding the labelling index, a significant association was observed between these two values (by Spearman rank correlation test; r = 0.609, P <0.01). So the average of these two values was used for the study.
Statistical methods
The relationship between MVC, PCNA LI and clinicopathological factors was examined by the Wilcoxon rank sum test. Survival curves were calculated using the Kaplan-Meier method and analysed by the log-rank test. The influence of each variable on survival was assessed by Cox's proportional hazard model (Cox, 1972) . The relationship between MVC, PCNA LI, various clinicopathological factors and the mode of recurrence was examined by chi-square test or logistic regression analysis. Statistical significance was defined as P <0.05.
Results
MVC and PCNA LI Microvessel count ranged from 5.1 to 50.0 with a mean value, plus or minus the standard deviation, of 15.9 ± 10.3. PCNA LI ranged from 7.7% to 76.5% with a mean value of (Figure 3b ). The effects of variables presumably associated with prognosis were studied by Cox's proportional hazard model. As a result, only MVC and PCNA LI emerged as independent prognostic factors (Table III) . Of these parameters, PCNA LI was the most important factor for predicting overall survival, followed by MVC.
The relationship between the mode of recurrence, MVC and PCNA LI With regard to the site of the first relapse, 11 patients had hepatic recurrences, 13 had peritoneal recurrences and five had other sites of recurrence. The relationship between MVC, PCNA LI and recurrence is shown in Table IV . Of the patients with high-MVC tumours, 11 (57.9%) had hepatic recurrence and seven (36.8%) had peritoneal recurrence. In contrast, in patients with low-MVC tumours, six (60%) had peritoneal recurrence and none had hepatic recurrence. The frequency of hepatic recurrence was significantly (P<0.01) higher in patients wtih high-MVC tumours than in those with low-MVC tumours. In contrast, there was no significant correlation between PCNA LI and the site of recurrence.
The rates of recurrence subdivided according to MVC and PCNA LI are shown in Figure 4 . The rate of recurrence was only 2.4% (1/42) in patients with low-MVC and low-PCNA recurrence by logistic regression analysis. Only MVC was associated significantly with hepatic metastasis. However, PCNA LI was not associated with any type of the recurrence (Table V) .
Discussion
It is now well established that vascularity and proliferative activity play key roles in tumour growth, invasiveness and metastasis (Van Dierendonck et al., 1989; Folkman, 1992; Weidner et al., 1993 thesis and is thought to be expressed in the nuclei particularly in late G1 and S-phases (Garcia et al., 1989; Landberg et al., 1990) . In this study, we used PCNA LI as a marker for cell proliferation. As a result, we found that the higher grade of PCNA expression was observed in patients with lymph node metastasis or serosal invasion. Yonemura et al. (1993) reported higher PCNA expression in patients with tumours of diameter 6 cm or more and with lymph node metastasis. With regard to prognosis, our study demonstrated significantly poorer prognosis in patients with high-MVC tumours or high-PCNA LI tumours, and both MVC and PCNA LI were independent significant prognostic factors. Weidner et al. (1992) have shown that both relapse-free and overall survival rates decrease with increasing MVC. Toi et al. (1993) have also reported that MVC is an independent prognostic factor in patients with breast cancer. Similarly, Yonemura et al. (1993) have reported that, among 120 patients with gastric cancer, those with a high PCNA LI (40% or greater) had a significantly poorer prognosis than those with a low PCNA LI (less than 40%). Furthermore, with regard to sites of recurrence, an increased MVC was significantly associated with hepatic recurrence. These results suggest that both MVC and PCNA LI are prognostic indicators and that MVC is an effective predictor of hepatic recurrences in patients with gastric carcinoma.
Tumour cells are rarely shed into the circulation before the primary tumour is vascularised (Folkman, 1990) . It has been shown that greater numbers of tumour vessels increase the opportunity for tumour cells to enter the circulation (Liotta et al., 1976) . Moreover, newly formed capillaries have fragmented basement membranes and are leaky compared with mature vessels, making them penetrable by tumour cells (Nagyl et al., 1988) . Therefore, in the high-MVC tumours, the metastatic process may be enhanced by the leaky nature of newly formed blood vessels, which facilitates vascular invasion. Our results confirm the association between high vessel count in gastric carcinoma and the risk of hepatic recurrence.
Various adjuvant therapies have been given to patients with advanced gastric cancer to prevent recurrence after resection. However, 50% of patients with advanced gastric cancer survive after curative resection without post-operative therapy (Miwa, 1984) . Therefore, patients who need adjuvant therapies should be selected by some indicators reflecting the probability of recurrence. Thus, MVC and PCNA LI in resected specimens may be suitable methods of identifying patients who need additional therapy post-operatively.
Recently, TNP-470, an analogue of fumagillin derived from Aspergillus fumigatus, has been shown to inhibit angiogenesis and the growth of some tumours (Ingber et al., 1990; Yamaoka et al., 1993) . Such agents may prove to be valuable anti-tumour chemotherapeutic agents, especially in patients with high-MVC tumours.
In summary, this retrospective study demonstrates that both MVC and PCNA.LI may be good prognostic indicators and that MVC may be useful in predicting the hepatic recurrence in patients with gastric carcinoma. If these findings are confirmed in larger studies, it will be possible to add MVC and PCNA LI to other prognostic factors to identify patients at high risk of recurrence and to guide decisions on additional therapy after surgery.
Abbrevations: F-VIII RA, factor VIII-related antigen; PCNA, proliferating cell nuclear antigen.
